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1607-551X/Copyright ª 2015, KaohsiuAbstract Roche modified the COBAS AmpliPrep/COBAS TaqMan human immunodeficiency vi-
rus type 1 (HIV-1) test version 1.0 (CAP/CTM v1.0), resulting in the COBAS AmpliPrep/COBAS
TaqMan HIV-1 test version 2.0 (CAP/CTM v2.0). The aim of this study was to evaluate the per-
formance of the CAP/CTM v2.0 and to compare this performance with that of the CAP/CTM
v1.0. The study was conducted in a small local study group in Kaohsiung Medical University Hos-
pital, Kaohsiung, Taiwan. A total of 86 plasma samples from HIV-1-seropositive patients were
tested using the two assays. The correlation and concordance of results between the two as-
says were calculated. The CAP/CTM v2.0 generated higher values than did the CAP/CTM v1.0,
and five samples (5.8%) yielded a difference of > 1 log10 copies/mL. In addition, our data show
that CAP/CTM v1.0 and CAP/CTM v2.0 yielded relatively consistent values for 23 samples with
low viral loads (< 200 copies/mL). Furthermore, when viral loads were in a medium range (2e5
log10 copies/mL), the results of the two assays were more compatible. This study shows a good
correlation between CAP/CTM v1.0 and v2.0 in HIV-1 viral load measurement. Furthereclare no conflicts of interest.
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Comparison of CAP/CTM v1.0 and v2.0 189attention must be paid to those cases in which measured viral loads present larger differences
between the two assays.
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reserved.Introduction
Globally, an estimated 35.3 million people were infected
with human immunodeficiency virus (HIV) in 2012 [1]. In
Taiwan, 24,239 people were infected with HIV, and 3771 in-
dividuals died of AIDS up until December 2012 [2]. There are
approximately 2000 new HIV infections annually in Taiwan.
The plasma viral load serves as a direct indicator of HIV
replication and is correlated with immune destruction.
Therefore, this viral load is considered to be an important
prognostic marker for evaluating a patient’s response to
antiretroviral therapy (ART) and for monitoring HIV disease
progression [3,4]. According to the United States Depart-
ment of Health and Human Services’ HIV treatment guide-
lines, optimal viral suppression by ART is generally defined
as an HIV type 1 (HIV-1) viral load persistently below the
limit of detection, which is < 20e75 copies/mL, depending
on the assay used [5].
Currently, several commercial HIV-1 viral load assays are
available. The principles of these assays include reverse
transcriptase polymerase chain reaction, nucleic acid
sequence-based amplification (NASBA) and signal amplifi-
cation techniques [branched DNA (bDNA)] [6e9]. At present,
the development of real-time detection techniques and
automated sample preparation has provided many advan-
tages, such as: (1) rapid and less labor-intensive nucleic acid
extraction; (2) a reduced risk of contamination due to the
use of a closed system; and (3) significantly improved
detection ranges [10,11]. Two Food and Drug Administra-
tion-approved real-time HIV-1 viral load assays were avail-
able in 2007: (1) the Roche COBAS AmpliPrep/COBAS TaqMan
HIV-1 test version 1.0 (CAP/CTM v1.0) (Roche Molecular
Systems, Pleasanton, CA), which utilizes standard TaqMan
chemistry to target the HIV-1 gag gene; and (2) the Abbott
Molecular RealTime HIV-1 assay (Abbott HIV) (Abbott, Chi-
cago, IL), which utilizes a novel, partially double-stranded
probe design targeting the HIV-1 integrase gene [12,13].
Several reports have shown that the two tests correlate well
in HIV-1 viral load quantitation [14e17]. However, the CAP/
CTM v1.0 is considered to be more sensitive than the Abbott
HIV for the quantification of low viral load [16,18e20]. The
major drawbacks reported for the CAP/CTM v1.0 are: (1)
limited specificity owing to genetic diversity or genotype
inclusivity; and (2) lower sensitivity with an increased false
negative rate [21e23]. To improve the test’s genetic di-
versity and genotype inclusivity, Roche modified the CAP/
CTM v1.0, resulting in the COBAS AmpliPrep/COBAS TaqMan
HIV-1 test version 2.0 (CAP/CTM v2.0), which simultaneously
amplifies and detects two targets (gag and Long terminal
repeat) in the HIV-1 genome. The production of the CAP/
CTM v1.0 has been stopped. The aim of this study was to
evaluate the performance of the CAP/CTM v2.0 and to
compare its performance with that of the CAP/CTM v1.0.Materials and methods
Clinical samples
This evaluation was performed retrospectively using 86
EDTA-plasma specimens from patients who were confirmed
to be HIV-1 seropositive and receiving ART. These EDTA-
plasma samples were submitted to our laboratory for
routine HIV-1 viral load testing by the CAP/CTM v1.0. EDTA-
blood tubes were centrifuged at 1450g for 15 minutes prior
to the plasma being separated into two aliquots in 1 mL
vials and stored at 80C until the time of testing.Viral load assays
The viral loads of these samples were measured using two
commercial kits according to the manufacturer’s in-
structions. The plasma HIV-1 RNA levels were determined
as copies/mL in both assays.
Roche CAP/CTM v1.0
Viral RNA was extracted automatically and transferred to
the COBAS TaqMan system for amplification and detection.
All methods and procedures were performed as stated in
the CAP/CTM v1.0 kit insert. The results are given in
copies/mL. The detection range of the CAP/CTM v1.0 is
from 40 copies/mL to 107 copies/mL.
Roche CAP/CTM v2.0
The CAP/CTM v2.0 was implemented along with the COBAS
AmpliPrep automated nucleic acid extractor and TaqMan 96
analyzer. The quantification range of the CAP/CTM v2.0 is
from 20 copied/mL to 107 copies/mL.
Controls
Each run consisted of tested samples and one high-positive
control, one low-positive control, and one negative control
from the kits.Statistical analysis
The statistical analysis was performed using SPSS version
19.0 software (SPSS Inc., Chicago, IL, USA). All HIV-1 viral
load values were converted into log10 copies/mL. The
mean, standard deviation (SD) and coefficient of variation
(CV) were calculated for both assays. The strength of the
linear relationship between the two assays was compared
using Pearson’s correlation, and the regression coefficient
(R) was calculated. The degree of agreement between the
two assays was assessed by the Bland-Altman method [24].
Table 2 Human immunodeficiency virus type 1 (HIV-1)
RNA loads in 86 EDTA-plasma samples, as measured by
COBAS AmpliPrep/COBAS TaqMan HIV-1 test (CAP/CTM)
version 1.0 (v1.0) v1.0 and CAP/CTM v2.0.
Mean of samples (range) SD CV
CAP/CTM v1.0 3.67 (1.63e7.00) 1.32 0.36
CAP/CTM v2.0 4.00 (1.30e6.21) 1.35 0.34
The dynamic ranges (log10 copies/mL) of CAP/CTM v1.0 and v2.0
are 4.0 Eþ1 to 1.0 Eþ7 and 2.0 Eþ1 to 1.0 Eþ7, respectively.
CV Z coefficient of variation; SD Z standard deviation.
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In total, 86 HIV-seropositive plasma samples that were
collected for routine testing by the CAP/CTM v1.0 were
subsequently tested by the CAP/CTM v2.0. The clinical and
demographic characteristics of 86 patients in this study are
summarized in Table 1.
Measurement of HIV-1 viral loads
The two assays measured HIV-1 viral loads within a dynamic
range in all 86 samples. The average viral loads (log10
copies/mL) in the 86 samples measured by CAP/CTM v1.0
and CAP/CTM v2.0 were 3.67 (SD Z 1.32) and 4.00
(SD Z 1.35), respectively (Table 2). The mean log10 dif-
ference between the two assays (CAP/CTM v2.0eCAP/CTM
v1.0) for all 86 samples was 0.37 (0.54e1.62, SDZ 0.42).
CAP/CTM v2.0 yielded higher viral load in 64 cases, CAP/
CTM v1.0 in 14 cases, and viral loads of the other six cases
were nondetected by both methods. The results indicate
that the HIV-1 viral loads determined by the CAP/CTM v2.0
were higher than those determined by the CAP/CTM v1.0.
Comparisons of the CAP/CTM v2.0 with CAP/CTM v1.0 as a
reference showed that under 1 log10 copies/mL, a differ-
ence was found in 81 cases among the 86 samples. By
contrast, five samples showed significantly higher quantifi-
cation, with a difference of > 1 log10 copies/mL, by the
CAP/CTM v2.0 (Table 3).Table 1 The clinical and demographic characteristics of
86 patients in this study.
Characteristic Number of samples
Sex
Male 33
Female 43
Unknown 10
Age (y)
18e29 24
30e39 25
40e49 20
50e59 5
 60 2
Unknown 10
CD4þ count (cells/mL)
 200 15
201e350 30
351e500 20
> 500 11
Unknown 10
Receiving antiretroviral medication
NRTI þ PI 21
NRTI þ NNRTI 20
NRTI þ II 2
NRTI þ PI þ II 2
NRTI þ PI þ NNRTI 1
No treatment 30
Unknown 10
II Z integrase inhibitor; NNRTI Z non-nucleoside reverse
transcriptase inhibitor; NRTIZ nucleoside reverse transcriptase
inhibitor; PI Z protease inhibitor.Linear correlation coefficient
Fig. 1 shows a significant linear correlation between CAP/
CTM v1.0 and CAP/CTM v2.0 (coefficient of determination,
R2Z 0.92). For all 86 samples within the dynamic ranges of
both assays, a plot of the differences between the two
assays was established by Bland-Altman analysis (Fig. 2).
The mean difference between the two assays (CAP/CTM
v2.0eCAP/CTM v1.0) was 0.37 log10 copies/mL
(0.54e1.62), with an SD of 0.42. The 2SD and þ2SD
values for the individual log10 differences were 0.46 and
1.21, respectively. The graph indicates no significant dif-
ference between the two assays.
Mean difference, in log10 copies/mL, in the viral
load range
The viral load data were further broken down into defined
ranges (Table 4). The mean differences (v2.0ev1.0), in
log10 copies/mL, were high for logZ 2e3 (0.54), logZ 3e4
(0.64), and logZ 4e5 (0.44). By contrast, there was less of
a difference between CAP/CTM v1.0 and CAP/CTM v2.0 in
low viral load ranges (log < 1, log Z 1e2) and high viral
load ranges (log Z 5e6, log Z 6e7). However, when we
calculated the CV of the difference for these groups, lower
CV values were found in the groups of medium range
(logZ 2e5; Table 4). In total, viral loads were < 200 copies
in 23 samples, as measured by the CAP/CTM v1.0. Among
these samples, six samples were classified as no target
detected (NTD) after measurement by both methods. Viral
loads were detected in 14 samples, but < 200 copies/mL by
both methods. In particular, three samples with viral loads
< 200 copies/mL, as measured by the CAP/CTM v1.0, were
found to have viral loads > 200 copies/mL using the CAP/
CTM v2.0 (Table 5).
Discussion
The viral load and CD4þ T cell counts are two markers for
assessing the level of HIV-1 viremia in and the immune
function of infected patients. Therefore, accurate and
sensitive measurement of the HIV-1 viral load is essential to
provide clinicians with valuable information to make
treatment decisions. Many reports have indicated that the
CAP/CTM v1.0 has serious underestimation problems
[25,26]. To solve these problems, Roche developed the
CAP/CTM v2.0 in 2009, which includes additional primers
Table 3 The mean difference in viral loads was over 1
log10 copies/mL between COBAS AmpliPrep/COBAS TaqMan
HIV-1 test (CAP/CTM) version 2.0 (v2.0) and CAP/CTM v1.0
in five samples.
Sample
ID
CAP/CTM v1.0 CAP/CTM v2.0 Log10
copies/mL
difference
(v2.0ev1.0)
Copies/
mL
Log10
copies/mL
Copies/
mL
Log10
copies/mL
120672 982 2.99 9965 4 1.01
120703 2284 3.36 24294 4.39 1.03
120725 24894 4.40 338268 5.53 1.13
120860 359 2.56 15008 4.18 1.62
120942 777 2.89 8198 3.91 1.02
Figure 2. Bland-Altman plot showing the difference in viral
loads between COBAS AmpliPrep/COBAS TaqMan HIV-1 test
(CAP/CTM) version 1.0 (v1.0) and v2.0 (v2.0ev1.0). The mean
and the mean þ 2 standard deviation (SD) values are indicated
by the heavy unbroken and broken lines, respectively.
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HIV-1.
This study evaluated the performance of the new CAP/
CTM v2.0 and the CAP/CTM v1.0 using EDTA-blood samples
from 86 HIV-1-seropositive patients. The data obtained
from these two assays showed a strong linear correlation,
but the CAP/CTM v2.0 yielded higher viral load values than
did the CAP/CTM v1.0. Bland-Altman analysis also demon-
strated that the difference between these two assays was
low. These findings are similar to those of previous reports
[19,20,27e29]. The average viral loads (log10 copies/mL) in
these 86 samples, as measured by CAP/CTM v1.0 and CAP/
CTM v2.0, were 3.67 and 4.00, respectively. Similar reports
indicated that the mean viral loads determined by the CAP/
CTM v2.0 were higher than the loads determined by CAP/
CTM v1.0 [19,20,27,28]. It is possible that the difference
may be due to the addition of a second set of primers and
probes in CAP/CTM v2.0. This methodology renovation can
detect more gag mutated strains which were under
detectable by CAP/CTM v1.0. The overall mean differenceFigure 1. Linear relationship between COBAS AmpliPrep/
COBAS TaqMan HIV-1 test (CAP/CTM) version 1.0 (v1.0) and
CAP/CTM v2.0. Observation of the two assays, showing a linear
relationship (coefficient of determination, R2 Z 0.92).between these two assays (CAP/CTM v2.0eCAP/CTM v1.0)
was 0.37. A difference of < 0.5 log10 copies/mL is generally
accepted as clinically relevant [30]. However, five of 86
samples (5.8%) were found to exhibit clinically relevant
differences (> 1 log10 copies/mL) between CAP/CTM v2.0
and CAP/CTM v1.0. Similar results have been reported
[20,27,28,31]. There are two possible explanations for the
above difference: (1) the CAP/CTM v1.0 underestimated
viral loads; or (2) the CAP/CTM v2.0 overestimated copy
numbers. Because the gag gene has a higher incidence of
mutation, it is possible that the CAP/CTM v1.0 was not able
to detect a mutated strain. By contrast, the CAP/CTM v2.0
includes primers and a probe for another highly conserved
region of the HIV-1 genome (50 LTR), in addition to the gag
primers and probe, to avoid the underestimation observed
in the CAP/CTM v1.0. It is possible that the CAP/CTM v1.0
underestimated the viral loads. Further observation must
be paid to survey whether CAP/CTM v2.0 overestimates the
viral load or the existence of other unknown confounding
factors. Thus, during the switch from the CAP/CTM v1.0 to
CAP/CTM v2.0, the laboratory has to notify clinicians of the
relevant information that the over 1 log10 copies/mL dif-
ference between CAP/CTM v2.0 and CAP/CTM v1.0 is due to
various possibilities besides ART failure.
The CAP/CTM v2.0 has been reported to quantify HIV-1
viral loads more sensitively and accurately than does CAP/
CTM v1.0 at low viral loads [32]. However, another paper
reported that the HIV-1 viral loads determined by the CAP/
CTM v2.0 at < 200 copies/mL are lower compared with the
loads determined by the CAP/CTM v1.0 [20]. Our data show
that CAP/CTM v1.0 and CAP/CTM v2.0 were relatively
consistent in 23 samples with low viral loads (< 200 copies/
mL). Among these samples, HIV-1 RNA was not detected in
six samples (NTD). Viral loads were detected in the other 14
samples, but with values < 200 copies/mL, by both CAP/
CTM v1.0 and CAP/CTM v2.0. In three samples, viral loads
were detected as being < 200 copies/mL by the CAP/CTM
Table 4 The viral load ranges were grouped according to the COBAS AmpliPrep/COBAS TaqMan HIV-1 test (CAP/CTM) version
1.0 (v1.0).
v1.0 viral load ranges
(log10 copies/mL)
No. of samples Mean log10 copies/mL
difference (range) (v2.0ev1.0)
SD
(v2.0ev1.0)
CV
(v2.0ev1.0)
< 1 6
1e2 13 0.15 (0.54e0.6) 0.34 2.28
2e3 15 0.54 (0.17e1.62) 0.48 0.88
3e4 16 0.64 (0.3e1.03) 0.25 0.38
4e5 19 0.44 (0.09e1.13) 0.28 0.65
5e6 13 0.10 (0.3e0.51) 0.21 2.07
6e7 4 0.04 (0.1e0) 0.05 1.32
All 86 0.37 (0.54e1.62) 0.42 1.13
CV Z coefficient of variation.
Table 5 Concordance of low viral loads (< 200 copies/mL) determined by the COBAS AmpliPrep/COBAS TaqMan HIV-1 test
(CAP/CTM) version 1.0 (v1.0) compared with the CAP/CTM v2.0.
CAP/CTM v2.0 CAP/CTM v1.0
NTD,
< 40 copies/mL
Detected,
< 40 copies/mL
Detected,
40e200 copies/mL
NTD, < 20 copies/mL 6 0 0
Detected, < 20 copies/mL 0 0 0
Detected, 20e200 copies/mL 0 1 13
Detected, > 200 copies/mL 0 0 3
NTD Z no target detected.
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for NTD could be: (1) a complete absence of residual
viremia; or (2) further mutated strains that could not be
detected by either assay. Therefore, beyond viral loads,
CD4 counts are a very important marker for clinicians to use
to assess the efficacy of ART.
When the HIV-1 viral loads in the 86 samples were
grouped into different ranges, we found that the mean
differences between CAP/CTM v2.0 and CAP/CTM v1.0 at
low viral loads (< 2 log10 copies/mL) and high viral loads (>
5 log10 copies/mL) were lower (0.04e0.15 log10 copies/mL)
than at medium viral loads (2e5 log10 copies/mL)
(0.44e0.54 log10 copies/mL). These results were different
from the findings of a report that indicated that the mean
difference between CAP/CTM v2.0 and CAP/CTM v1.0 was
greater at low-to-medium viral loads [19]. Interestingly,
when we calculated the CV of the difference for these
groups, lower CV values were found in the groups of me-
dium range. This finding indicates that when viral loads are
in medium range, the difference between the two assays is
more homogeneous.
There are limitations in this study. Parts of our samples
are referred samples and some samples are anonymous
screen in our hospital. We are unable to get more samples
for mutation analysis and subtyping. In fact, different
subtypes and mutations may impact the outcome measure
[22,33]. This is a cross-sectional study, and we need more
observations and clinical correlations to validate the per-
formance of HIV viral load determination. It is very often
the case that laboratory data did not always meet the
expectation of clinicians. Intermachine or intermethoddiscrepancy biased the outcome measure. Communication
between interdiscipline personnel is mandatory to solve
clinical conundrums.
So far, there have been many publications about the
assessment of different kits for HIV-1 viral load measure-
ment. However, this is the first report comparing two HIV-1
viral load quantification assays in Taiwan. In conclusion,
this study shows a good correlation between CAP/CTM v1.0
and CAP/CTM v2.0 in HIV-1 viral load measurement. The
CAP/CTM v2.0 seems to be more sensitive than CAP/CTM
v1.0. Further attention must be paid to those cases whose
measured viral loads exhibited larger differences between
the two assays. In addition to the fact that mutated strains
could bias the result, other possibilities should be consid-
ered. Clinicians should be alerted to find possible mecha-
nisms to elucidate the conflicting results.References
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